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Received January 17, 2012; accepted June 26, 2012AbstractLyme disease is the most commonly reported vector-borne illness in the United States, but it is relatively rare in Taiwan. Lyme disease can be
treated with antibiotic agents, but approximately 20% of these patients experience persistent or intermittent subjective symptoms, so-called
chronic Lyme disease (CLD). The mechanisms of CLD remain unclear and the symptoms related to CLD are difficult to manage.
Hyperbaric oxygen therapy (HBOT) was applied in CLD therapy in the 1990s. However, reported information regarding the effectiveness of
HBOT for CLD is still limited. Here, we present a patient with CLD who was successfully treated with HBOT.
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Lyme disease is an infectious disease with a worldwide
impact, caused by the tick-carried Borrelia burgdorferi bacte-
rium.1 In Taiwan, a laboratory-diagnosed human case of Lyme
disease had been reported in 1998, while the spirochetes related
to the causative agent, B. Burgdorferi sensu lato, were first iso-
lated from rodents in the Taiwan area.2,3 The medical diagnosis
of Lyme disease is based on a combination of manifestations,
including dermatological, rheumatological, neurological, and
cardiac abnormalities, as well as laboratory assays.4 EvidenceConflicts of interest: The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
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intervention occurs soon after infection.5 However, some pa-
tients will continue to suffer from chronic Lyme disease (CLD)
despite receiving an adequate course of therapy. 6
The precise mechanisms of CLD symptoms are unknown.
Hyperbaric oxygen therapy (HBOT) serves as a primary or
adjunctive therapy for a range of medical and surgical con-
ditions,7 and has been applied in therapy of CLD since the
1990s. We present a patient with CLD who was successfully
treated with HBOT.
2. Case report
InApril 2003, our patient was a 31-year-old healthymanwho
worked in the financial industry and lived in Taipei City, who
began suffering from intermittent low- and high-grade fever.
These symptoms were accompanied by fatigue and multiple
bone pain, especially in the sternum, ribs, and lower back, which
made it difficult for the patient to walk. Since that time, theociation. All rights reserved.
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painkillers. In January 2004, some erythema migrans lesions
were found over the patient’s legs. In addition, he suffered from
joint pain in both knees, the shoulders, and temporomandibular
joints. Tracing back the patient’s history 2 years prior to clinical
presentation, it was noted that he was a frequent hiker in the
Yang-Ming Mountains in Taipei, Taiwan, where he often sat on
the grass and had contact with wild cattle. He had previously
visited infection and dermatology clinics, where his Borrelia
serology IgG was positive, and Lyme disease was strongly
suspected. Soon thereafter, 500 mg amoxicillin twice daily was
prescribed for 1 month, which caused the patient’s symptoms to
subside partially. However, in the next 3 years, he was bothered
by symptoms including: (1) nervous system, comprised of ir-
ritability, mood swings, poor concentration, loss of short-term
memory, sleep disturbance, facial tingling, blurred vision, and
photophobia; (2) cardiovascular system, consisting of chest
pains and palpitations; (3) musculoskeletal system, associated
with migrating arthralgias; and (4) other problems, including
headache and pelvic pain.
In 2007, the patient again visited another infection clinic,
where he received antibiotic agents such as doxycycline, amox-
icillin 250 mgþ clavulanic acid 125mg (Augmentin), parenteral
penicillin, and oral cefuroxime over the following 4 years.
Because the above symptoms had not improved significantly, in
October 2011 the patient visited us for HBOT. Before HBOT,
some residual symptoms such as elbow and joint pain, numbness
of the extremities, perioribital twitch, sleep disorder, and affected
thinking ability persisted. After we excluded other infectious and
noninfectious etiologies that canmimic certain appearances of the
typical multisystem illness seen in CLD, HBOT at 2.5 ATAwith
treatment duration of 1.5 hours for 30 sessions was given. In the
first 10 sessions of HBOT, nervous-system-associated symptoms
such as loss of thinking ability and sleep disorder disappeared. In
the second 10 sessions of HBOT, additional nervous system
symptoms such as numbness of the extremities and perioribital
twitch also disappeared. In the third 10 sessions of HBOT,
musculoskeletal system symptoms such as migrating arthralgia
also vanished. Overall, completion of 30 sessions of HBOT
caused noted longstanding Lyme-disease-related symptoms
affectingmost of the previously affectedbodily areas to disappear.
3. Discussion
Lyme disease was recognized in 1976 and is caused by the
tick-borne spirochete B. burgdorferi.1,8 In the United States, it
is the most common vector-borne illness, where >20,000
cases have been diagnosed annually. In Taiwan, Shih and Chao
conducted a zoonotic survey for evaluating spirochetal infec-
tion of rodents in Taiwan. They reported that the overall
infection rate throughout Taiwan was 16.6%, and the highest
infection rate (25.8%) was observed on Kimman Island. By
contrast, the infection rate in Taipei area was only 6.7%.3,9
Erythema migrans or “bulls-eye” rash following receipt of a
tick bite and joint swelling typical of arthritis are the classic
clinical appearances of Lyme disease. However, only 50e60%
of patients remembered having received a tick bite, and oftenthe skin lesion was either absent or atypical.10 Other mani-
festations such as multiple nonspecific symptoms that affect
different organ systems, including the joints, muscles, nerves,
brain, and heart are also reported.
Lyme disease is a clinical diagnosis. Laboratory testing
with a two-tier testing system is advocated by the Centers for
Disease Control and Prevention (CDC), United States, which
involves a positive screening test using an enzyme-linked
immunosorbent assay or immunofluorescence assay, fol-
lowed by positive Western blotting. The two-tier system has a
high specificity (99e100%); however, it has relatively poor
sensitivity (50e75%).11 Therefore, the tests used to diagnose
Lyme disease should be used to support rather than replace the
physician’s judgment.12 That is, the diagnosis is based on a
possible tick exposure history, the emergence of specific
clinical symptoms, and exclusion of other causes of the
symptoms. The results of serological or other diagnostic tests
are not essential. In most cases, Lyme disease can be treated
successfully with oral forms of antibiotics and a parenteral
regimen lasting 7e21 days, depending upon the different
presentations of the disease.5 However, 10e20% of patients
have persistent or intermittent subjective symptoms (such as
fatigue, arthralgia, myalgia, headache, neck stiffness, pares-
thesia, sleeplessness, irritability, and difficulty with memory,
word finding, and concentration) after receiving an adequate
course of antibiotic therapy. Lacking any alternative diagnosis,
such patients are classified as CLD.6 The mechanisms of CLD
are not clear. Possible explanations include persistent infection
with B. burgdorferi (although clinical or laboratory evidence
of infection is not required),6 postinfective fatigue syndrome,
and autoimmune mechanisms. With the pathophysiological
complexity of Borrelia, CLD is a controversial illness. Mul-
tiple body systems can be involved and they can be difficult to
manage.13 Prolonged antibiotic therapy has been used in pa-
tients who have CLD, but research suggests that such an
approach is not warranted.14e16
Several adjunctive therapies including immune system
therapy, ozone therapy, vaccination, and HBOTwere previously
mentioned. Among these therapies, HBOT has been recom-
mended for treatment of Lyme borreliosis, especially for pa-
tients who have received antibiotic therapy but still suffer from
Lyme-related symptoms.17 HBOT, a treatment in which the
patient intermittently breathes 100% oxygen while the treat-
ment chamber is pressurized to a pressure greater than sea level
(1 ATA), is increasingly used in many areas of medical prac-
tice.18 Although the method of action of such a unique inter-
vention is not satisfactorily understood, some mechanisms such
as competing anaerobes by increasing tissue oxygen tensions,
inhibiting bacterial metabolic functions by increasing the gen-
eration of oxygen free radicals, enhancing leukocytes to kill
bacteria by facilitating the oxygen-dependent peroxidase sys-
tem, and improving the oxygen-dependent transport of certain
antibiotics have been determined to be efficacious.7 Austin
illustrated the effects of oxygen on B. burgdorferi in 1993 and
showed that the ambient levels of O2 and CO2 can affect the
infectious capacity of B. burgdorferi.19 Thereafter, the effect of
HBOT in CLD was reported by researchers at Texas A&M
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showed significant improvement of symptoms, including
mental confusion, pain, depression and fatigue, with approxi-
mately 70% of patients who showed a lasting benefit upon
follow-up examination.20 CLD is a complicated illness.
Although HBOT is not a regularly recommended therapy for
CLD in Taiwan, HBOT might be an effective adjunctive treat-
ment when a clinician is confronted with a patient with CLD.
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